Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.
Chun-Ting YangChen-Yi YangHuang-Tz OuShihchen KuoPublished in: Cardiovascular diabetology (2020)
This comparison study extends the supporting evidence for the cardiovascular safety of GLP-1ra to a broad spectrum of real-world T2D patients using GLP-1ra.
Keyphrases
- end stage renal disease
- rheumatoid arthritis
- chronic kidney disease
- newly diagnosed
- ejection fraction
- prognostic factors
- disease activity
- type diabetes
- ankylosing spondylitis
- systemic lupus erythematosus
- blood glucose
- metabolic syndrome
- patient reported outcomes
- systemic sclerosis
- interstitial lung disease
- idiopathic pulmonary fibrosis